About Cancer Gene Therapy
Cancer gene therapy is the treatment of cancer through gene therapy. The therapy uses genetically engineered vectors mostly viruses to deliver a gene into the individual's body. It can be used for both the prevention and treatment of disease. The major therapies used for the treatment are oncolytic virotherapy, gene transfer, and gene-induced immunotherapy. The rising prevalence rate of cancer has been a huge challenge for the global economies as the disease leads to high rate of mortality and economic losses.
Technavio’s analysts forecast the global cancer gene therapy market to grow at a CAGR of 20.63% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global cancer gene therapy market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Cancer Gene Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Adaptimmune
• bluebird bio
• Celgene
• Shanghai Sunway Biotech
• Shenzhen SiBiono GeneTech
• SynerGene Therapeutics
Other prominent vendors
• Altor BioScience
• Amgen
• argenx
• BioCancell
• GlaxoSmithKline
• Merck
• OncoGenex Pharmaceuticals
• Transgene
Market driver
• Rising geriatric population
• For a full, detailed list, view our report
Market challenge
• High cost of gene therapy treatment
• For a full, detailed list, view our report
Market trend
• Favorable government regulations for gene therapy programs
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Market landscape
• Market outline
• Market overview
• Market size and forecast
• Five forces analysis
PART 05: Pipeline analysis
PART 06: Market segmentation by therapy
• Oncolytic virotherapy
• Gene transfer
• Gene-induced immunotherapy
PART 07: Geographical segmentation
• Cancer gene therapy in Americas
• Cancer gene therapy market in EMEA
• Cancer gene therapy market in APAC
PART 08: Decision framework
PART 09: Drivers and challenges
• Market drivers
• Market challenges
PART 10: Market trends
• Partnerships and collaborations are changing the market scenario
• Favorable government regulations for gene therapy programs
PART 11: Vendor landscape
• Vendor landscape
PART 12: Key vendor analysis
• Adaptimmune
• bluebird bio
• Celgene
• Shanghai Sunway Biotech
• Shenzhen SiBiono GeneTech
• SynerGene Therapeutics
• Other prominent vendors
PART 13: Appendix
• List of abbreviations
List of Exhibits?
Exhibit 01: Approaches for gene therapy
Exhibit 02: Difference between somatic cell and germline cell gene therapy
Exhibit 03: Major diseases treatment studies done through gene therapy
Exhibit 04: Global cancer gene therapy market snapshot
Exhibit 05: Global cancer gene therapy market 2016-2021 ($ millions)
Exhibit 06: Five forces analysis
Exhibit 07: Pipeline molecules by vendors
Exhibit 08: Key clinical trials
Exhibit 09: Segmentation of global cancer gene therapy market by therapy 2016
Exhibit 10: Segmentation of global cancer gene therapy market by therapy 2016 and 2021 (%)
Exhibit 11: Process involved in oncolytic virotherapy
Exhibit 12: Global cancer gene therapy market by oncolytic virotherapy 2016-2021 ($ millions)
Exhibit 13: Percentage of various viruses used in the clinical trials of oncolytic virotherapy for different cancer types
Exhibit 14: Oncolytic virotherapy scenario through adenovirus
Exhibit 15: Ideal characteristics of oncolytic virotherapy
Exhibit 16: Global cancer gene therapy market by gene transfer 2016-2021 ($ millions)
Exhibit 17: Selected transferred genes under studies
Exhibit 18: Global cancer gene therapy market by gene-induced immunotherapy 2016-2021 ($ millions)
Exhibit 19: Segmentation of global cancer gene therapy market based on geography 2016 and 2021
Exhibit 20: Global cancer gene therapy revenue by geography 2016-2021 ($ millions)
Exhibit 21: Market scenario in Americas
Exhibit 22: Cancer gene therapy market in Americas 2016-2021 ($ millions)
Exhibit 23: Gene therapy research institutes in the US and Canada
Exhibit 24: Market scenario in EMEA
Exhibit 25: Cancer gene therapy market in EMEA 2016-2021 ($ millions)
Exhibit 26: Commercialization status of gene therapy in top five European countries (as of November 2016)
Exhibit 27: Gene therapy research institutes in Europe focusing on cancer treatment
Exhibit 28: Market scenario in APAC
Exhibit 29: Cancer gene therapy market in APAC 2016-2021 ($ millions)
Exhibit 30: Common side effects associated with the treatment of cancer with traditional methods
Exhibit 31: Side effects associated with oncology drugs
Exhibit 32: General side effects of radiotherapy
Exhibit 33: Potential advantages of gene therapy in cancer treatment
Exhibit 34: Potential risks of cancer gene therapy
Exhibit 35: Case study: Major adverse event that bought halt in the gene therapy clinical trial scenarios
Exhibit 36: Competitive structure analysis of global cancer gene therapy market
Exhibit 37: Adaptimmune: Key highlights
Exhibit 38: Adaptimmune: Strength assessment
Exhibit 39: Adaptimmune: Strategy assessment
Exhibit 40: Adaptimmune: Opportunity assessment
Exhibit 41: bluebird bio: Key highlights
Exhibit 42: bluebird bio: Strength assessment
Exhibit 43: bluebird bio: Strategy assessment
Exhibit 44: bluebird bio: Opportunity assessment
Exhibit 45: Celgene: Key highlights
Exhibit 46: Celgene: Strength assessment
Exhibit 47: Celgene: Strategy assessment
Exhibit 48: Celgene: Opportunity assessment
Exhibit 49: Shanghai Sunway Biotech: Key highlights
Exhibit 50: Shanghai Sunway Biotech: Strength assessment
Exhibit 51: Shanghai Sunway Biotech: Strategy assessment
Exhibit 52: Shanghai Sunway Biotech: Opportunity assessment
Exhibit 53: Shenzhen Sibiono GeneTech: Strength assessment
Exhibit 54: Shenzhen Sibiono GeneTech: Strategy assessment
Exhibit 55: Shenzhen Sibiono GeneTech: Opportunity assessment
Exhibit 56: SynerGene Therapeutics: Strength assessment
Exhibit 57: SynerGene Therapeutics: Strategy assessment
Exhibit 58: SynerGene Therapeutics: Opportunity assessment
